Technical Analysis for ATHX - Athersys, Inc.

Grade Last Price % Change Price Change
grade D 1.39 2.96% 0.04
ATHX closed up 2.96 percent on Friday, November 15, 2019, on 1.14 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
3 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ATHX trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
BB Squeeze Ended Range Expansion 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Resistance Bearish 2.96%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.96%
Bollinger Band Squeeze Range Contraction 2.96%
BB Squeeze Started Range Contraction 2.96%

Older signals for ATHX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
ATHX Chart by TradingView
Basic chart:
Profile
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Biotechnology Biopharmaceutical Health Life Sciences Pharmaceutical Industry Diseases Pharmaceuticals Diabetes Pharmacy Drug Discovery Clinical Trial Obesity Schizophrenia Inflammatory Bowel Disease Cardiovascular Disease Regenerative Medicine Design Of Experiments Pfizer Mesoblast Orthopedic Applications
Is ATHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 14 Athersys, Inc. 2019 Q3 - Results - Earnings Call Presentation
Nov 14 Healios Receives Notification of Orphan Designation for Acute Respiratory Distress Syndrome Clinical Program
Nov 11 Were Hedge Funds Right About Souring On Athersys, Inc. (ATHX)?
Nov 7 Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q3 2019 Results - Earnings Call Transcript
Nov 6 Athersys EPS beats by $0.01
Nov 6 Athersys Reports Third Quarter 2019 Results
Nov 3 Did You Manage To Avoid Athersys's (NASDAQ:ATHX) 36% Share Price Drop?
Oct 14 Athersys to Host Third Quarter Financial Results Call
Sep 25 PRO+ Small And Micro Newsletter: Boxlight, Mallinckrodt, The Habit
Sep 25 Athersys to Present at 2019 Cell & Gene Meeting on the Mesa
See more ATHX news...
Indicators
Indicator Value
52 Week High 2.15
52 Week Low 1.2
Average Volume 452,071
200-Day Moving Average 1.495
50-Day Moving Average 1.3616
20-Day Moving Average 1.321
10-Day Moving Average 1.328
Average True Range 0.0584
ADX 13.62
+DI 23.4342
-DI 17.4531
Chandelier Exit (Long, 3 ATRs ) 1.2548
Chandelier Exit (Short, 3 ATRs ) 1.3952
Upper Bollinger Band 1.3842
Lower Bollinger Band 1.2578
Percent B (%b) 1.05
BandWidth 9.568509
MACD Line 0.0
MACD Signal Line -0.0102
MACD Histogram 0.0102
Fundamentals Value
Market Cap 158.34 Million
Num Shares 114 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -5.35
Price-to-Sales 61.05
Price-to-Book 8.00
PEG Ratio -0.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.50
Resistance 3 (R3) 1.49 1.44 1.48
Resistance 2 (R2) 1.44 1.42 1.45 1.47
Resistance 1 (R1) 1.42 1.40 1.43 1.43 1.47
Pivot Point 1.37 1.37 1.38 1.38 1.37
Support 1 (S1) 1.35 1.35 1.36 1.36 1.31
Support 2 (S2) 1.30 1.33 1.31 1.31
Support 3 (S3) 1.28 1.30 1.30
Support 4 (S4) 1.29